Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
August 9, 2023
Earnings Call Speaker Segments
Salli Schwartz
executiveHi, everybody, and thanks for joining us for the earnings call covering Q2 of 2023. On today's call, we'll go over the financial results that were issued following the market's close, and we'll share some thoughts about our commercial activity, and after that we'll hold a Q&A session. Should you not have had an opportunity to look at the earnings release, you can locate it within the Investor Relations portion of our site, illumina.com. Here for Illumina today are Charles Dadswell, our Interim Chief Executive Officer and General Counsel, along with Joydeep Goswami, our Chief Financial Officer and Chief Strategy and Corporate Development Officer. Chuck is going to give everyone an update regarding where Illumina's business stands, and Joydeep will walk through the financial results, which take in GRAIL. Just a reminder that, under the interim measures handed down by the European Commission, which blocked our purchase of GRAIL under the EU Merger Regulation, GRAIL has to be kept and run in a separate and independent manner from Illumina. This call is being recorded, and the audio portion is going to be archived in the Investor section of our site; we intend for all forward-looking statements about our financial results and commercial activity that get made on today's call to be protected by the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. What actually happens or what we actually achieve could differ materially from what is projected or discussed. Every forward-looking statement rests on information currently available, and Illumina takes on no obligation to update any of these statements. So that you can better grasp the risks and uncertainties that might cause actual results to differ, please refer to the documents Illumina submits to the Securities and Exchange Commission, among them Illumina's most recent forms 10-Q and 10-K. With all of that said, I'll hand the call over to Chuck now.
Charles Dadswell
executiveThanks, Salli. Good afternoon, folks, and I appreciate everyone being on today's call. Two months have passed since I stepped into the interim CEO position here at Illumina, as all of you are aware. We're actively searching for a permanent CEO, and we hope to share news with you before long. The outstanding candidates our Board is meeting with have left them very encouraged. Before I walk through our second quarter results, I want to pause and express gratitude to Francis deSouza, our former CEO, and John Thompson, our former Chairman of the Board, for the care and dedication they showed during their time at Illumina. I'd also like to extend a welcome to the newest members of our Board: Stephen MacMillan, who now serves as our Chairman of the Board, along with Andrew Teno and Scott Ullem. I want to recognize some shifts on our executive leadership team as well, among them the exits of Alex Aravanis, our Chief Technology Officer, and Phil Febbo, our Chief Medical Officer. On behalf of everyone at the company, I wish them both great success going forward. We're also happy to share that Steve Barnard — who has spent 25 years at Illumina and is a renowned scientist in our field — will carry Illumina's innovation legacy forward as our incoming Chief Technology Officer; meanwhile, a search will be conducted for our next Chief Medical Officer. Now to our second quarter results: during Q2, Illumina brought in revenue of roughly $1.18 billion along with diluted non-GAAP EPS of $0.32, and both figures came in above the guidance we gave in Q1; 109 NovaSeq X instruments went out the door during the quarter, and we've raised our projection for full year supply capacity to over 390 instruments. That said, as our earnings release made clear, our guidance is being reduced, and we now anticipate core Illumina full year 2023 revenue will be roughly flat versus 2022, driven mainly by three things. First, a temporary drop in high throughput consumables that was bigger than expected as we move more customers than anticipated onto the NovaSeq X. Second, a great many of our customers continue to be more careful when it comes to purchasing. And last, in China, the economic rebound is dragging on longer while the competitive landscape grows ever tougher — unlike the Americas and Europe, where we continue to expect growth year-over-year in 2023. Joydeep will share further specifics about our revised guidance when he speaks. One topic I'd like to explore a bit more is the NovaSeq X rollout. This process has proven harder than we expected. NovaSeq X ranks as the most sophisticated platform we've ever brought to market and features the most comprehensive end-to-end software we've ever put out. On top of that, the X rollout has happened at a pace and scale never seen before. And we've found issues in the field that are normal for new product releases. To tackle these, we've taken steps that include a planned software update, which came out in June following our first customer shipment in March. Illumina technical teams have been sent around the world to collaborate with our customers and speed up getting their systems online. Although the NovaSeq X rollout is going to take more time than we had initially anticipated, the ongoing high level of interest and the capital commitments being made to buy these systems is still very encouraging. As of now, 20% of the customers who bought a NovaSeq X have placed orders for more than a single instrument. This early appetite for multiple instruments, and the capacity those instruments represent, highlights why we feel confident that customers intend to expand their sequencing work. There is clear intent among our customers to conduct more sequencing going forward: they have told us that larger-scale single cell and spatial analysis experiments become more feasible with the NovaSeq X, and they are seeking funding for those applications. Customers involved in large population genomics efforts have said they intend to run additional multiomic programs focused on population-specific variants, which could be used to create treatments for various demographics that work better within those populations. And, as some of you may have already heard, a number of our biggest customers are using the X to speed up their shift away from targeted panels and exomes toward whole genome sequencing. We anticipate that these kinds of projects will scale and ramp up soon, and we will stay closely engaged with our customers to meet their needs. We keep deliberately and actively lowering our cost structure and have sped up actions under the $100 million-plus annual run rate expense reduction program that we announced on our previous earnings call. As you saw in our late June 8K filing, we have cut our global headcount and are shrinking our global real estate footprint. We are also optimizing what we spend with third-party vendors and have lowered travel-related and other costs. For 2023, these measures are helping to offset the effect of lower full-year revenue on our operating margin. Going forward, these actions will keep supporting our margins and open up flexibility for additional investment in high-growth areas. Let me update you on a couple of our platforms: We saw sustained global interest in the NovaSeq X series during Q2, and we closed the quarter with over 260 orders since launch. Our shipments of 109 NovaSeq X instruments in Q2 came in above our expectation of 80 for the quarter and lifted our total installed base to 176 instruments. We now anticipate shipping more than 390 NovaSeq X instruments this year, an increase from the 330 we had previously expected for the year. In mid-throughput, we shipped roughly 160 NextSeq 1k/2k units in the second quarter, which is an 8% year-over-year increase, as customers either expanded their existing fleets or moved over from the MiSeq or NextSeq 550. Over 20% of NextSeq 1k/2k units in Q2 went to new-to-Illumina customers; we are still seeing lengthened sales cycles, sometimes because customers need time to raise funding or decide how to prioritize their investment dollars, and other times because they go through longer procurement processes. Outside of China, our win rate for the midthroughput segment went up versus the first quarter, and we see plenty of room ahead for differentiation in the 1k/2k, especially once X-LEAP SBS chemistry becomes available on those instruments next year. Turning to our markets: during Q2, clinical accounted for roughly 53% of total sequencing consumables revenue. On the oncology side, reimbursement for next generation sequencing-based testing kept advancing. Anthem, which is the second largest commercial payer in the US, along with Blue Cross Blue Shield of Michigan, each began covering comprehensive genomic profiling for advanced cancer patients, which brings over 30 million additional covered lives. Coverage also kept moving forward in Europe, where Switzerland now reimburses large next generation sequencing panels, comprehensive genomic profiling among them. Illumina's market leading TruSight Oncology assay, TSO 500, is still expected to surpass more than $100 million in 2023 revenue. Higher utilization and wider adoption of our assay remain the growth drivers. During Q2, we also finished our TSO Comprehensive submission for IVD registration in the United States. Still in oncology, GRAIL keeps making solid headway in adoption of its Galleri multi-cancer early detection test; in Q2, GRAIL hit its 100,000th commercial Galleri test milestone, and more than 7,500 providers in the US have now prescribed the test, with orders placed in over 80 health systems.
Charles Dadswell
executiveTo give you a quick update on the NHS-Galleri study: during the second quarter, GRAIL wrapped up the second-year follow-up visits, with 130,000 participants coming back, which works out to a retention rate of 91.3%. Invitations for the third and final-year visits are now going out, and the first appointments for those visits should happen this fall. The evidence behind Galleri keeps building. At the latest annual meeting of the American Society of Clinical Oncology, GRAIL shared results from the University of Oxford-sponsored SYMPLIFY study, showing high specificity, positive predictive value, and accuracy for both the cancer signal detected and cancer signal origin prediction, and also demonstrating that an MCED test can feasibly help clinicians make referral decisions coming from primary care physicians. GRAIL is also advancing its unique multi-cancer minimal residual disease test. At the American Association for Cancer Research annual meeting, GRAIL and AstraZeneca presented new data supporting the use of GRAIL's methylation platform to find residual cancer in post-treatment settings. In patients with relapsed or refractory disease across six hematological malignancies, GRAIL's technology achieved a cancer detection rate of 92%. These findings show that GRAIL's blood-based methylation approach gives clinicians additional options as they assess patients in efforts to reach remission and improve survival. Back to core Illumina: in reproductive health in the US, five state Medicaid programs — Louisiana, Michigan, North Carolina, Rhode Island and Tennessee — updated their policies and now cover non-invasive prenatal testing for all pregnancies. In Europe, NIPT is now available for all pregnancies in the Netherlands and has been approved for broader coverage in Italy. Now to our research and applied markets: as we announced in mid-July, the Alliance for Genomic Discovery, which Illumina and Nashville Biosciences launched in 2022, now has five founding members — AbbVie, Amgen, AstraZeneca, Bayer, and Merck — and represents a novel, industry-led collaboration aimed at speeding therapeutic development through large-scale genomics. Members will co-fund whole-genome sequencing of 250,000 samples and all get access to the resulting data for drug discovery and therapeutic development. The first phase of the Alliance was announced in January and involved whole-genome sequencing for 35,000 samples, primarily consisting of DNA from individuals of African ancestry. Before we turn to Joydeep and then move to Q&A, I wanted to highlight a couple of other innovations we recently announced. In June, our PrimateAI-3D, an AI algorithm that predicts disease-causing genetic mutations in patients with unprecedented accuracy, was featured in articles and as the cover story of Science magazine's June issue. And in July, we announced the newest version of our DRAGEN software for analyzing next-generation sequencing data. DRAGEN 4.2 expands award-winning accuracy while combining flexibility and scalability to enable efficient workflows and pull meaningful insights from genomic data; it improves identification of the causes of genetic disease and further helps with both drug discovery and population genomics analysis. Even though this year has unfolded differently than we had anticipated, our attention stays fixed on executing well, pushing innovation forward, and standing behind our customers as they bring their NovaSeq X instruments up to full capacity. We keep making headway on improving margins, even as we put priority on funding proprietary technology — the kind that yields differentiated products our customers value and that will fuel growth. Among these are launches still to come, such as the 25B flow cell for the NovaSeq X, which many are eagerly awaiting, the Illumina Complete Long Reads enrichment assay, and XLEAP-SBS chemistry on NextSeq 1k/2k, along with upcoming offerings aimed at emerging markets such as proteomics, multiomics, and spatial, areas where we spot chances to meet researchers' needs and provide complete, integrated, and accessible workflows. Put simply, Illumina will keep producing impactful outcomes. We give researchers and clinicians the data and technology required to make life-changing discoveries and decisions for patients. Our employees feel proud to share in Illumina's mission of improving human health by unlocking the power of the genome; and as the global engine of genomics innovation, we are positioned both now and going forward to maximize shareholder value. With that, I'd like to hand the call to Joydeep for more detail on our results and outlook, and from there we'll move to Q&A. Joydeep?
Joydeep Goswami
executiveThanks, Chuck. First off, I want to take you through the numbers for the whole company, after that I'll go over how each segment did — core Illumina and GRAIL — and I'll wrap up by sharing my thoughts on what 2023 looks like from where we sit. What I'm going over are non-GAAP figures, and those do factor in stock-based compensation. I'd suggest you review the GAAP reconciliation for these non-GAAP metrics, which is available both in the release we put out today and in the supplementary data on our site. As Chuck mentioned, consolidated revenue for the second quarter came in at $1.18 billion, which represents an 8% increase over the first quarter of 2023 and came in above the top end of our guidance range, driven by shipments of NovaSeq X that were stronger than we had expected. On a year-over-year basis, consolidated revenue rose 1%, and it was up 3% in constant currency. Non-GAAP net income reached $50 million, or $0.32 per diluted share, and that figure includes dilution from GRAIL's non-GAAP operating loss, which was $164 million for the quarter. We beat our own forecast for non-GAAP EPS, and the main drivers were continued progress on cutting costs, a better gross margin than anticipated, and stronger top-line results during the quarter. For the quarter, our non-GAAP tax rate reached 39.3%, compared with 25.8% in Q2 2022, and both periods include the effects of the R&D capitalization rules. Although the R&D capitalization rules produced the same dollar amount of non-GAAP tax expense in each period, the hit to our effective tax rate was bigger in Q2 2023 since our profits were smaller. Non-GAAP diluted shares, on a weighted average basis, totaled about 158 million for the quarter. Let's turn now to how each segment performed. Revenue at Core Illumina came in at $1.16 billion, which is essentially level with the prior-year period, or a 2% gain when currency effects are stripped out. That figure reflected a roughly 180-basis-point hit that had been anticipated from COVID surveillance. In Q2 2023, COVID surveillance contributed around $6 million to overall revenue, down from $27 million in Q2 2022. Sequencing consumables at Core Illumina brought in $739 million, down 1% from the same quarter last year. Clinical saw growth in the mid-teens, powered by ongoing strength in oncology and genetic disease testing. That said, anticipated headwinds hit research. Those included about 260 basis points of decline tied to COVID surveillance, plus sanctions involving Russia. We also saw an impact on NovaSeq 6K consumables, since customers are starting to move to NovaSeq X but haven't yet gotten up to full speed on it. Constrained funding is another factor weighing on many customers globally. On our connected high- and mid-throughput instruments, total sequencing activity increased 3% compared with Q1 2023 and 9% year-over-year. Research and applied came in flat relative to Q1 and dropped 1% year-over-year. Clinical sequencing activity kept up its strong growth, up 6% versus Q1 and 23% year-over-year. Just to note, we treat these figures as a useful benchmark showing broad patterns of activity within our installed systems, and they tend to move in the same direction as revenue over the long run. Up to now, we've reported this using the count of sequencing runs, but starting now those metrics will be given as gigabases sequenced, since that gives a clearer picture of activity trends amid the large gains in output per run driven by NovaSeq X and NextSeq 1K/2K. Revenue from Core Illumina sequencing instruments reached $193 million, up 2% from the same period a year earlier. Shipments of NovaSeq X came in stronger than we had expected, and that more than made up for the decline we anticipated in NovaSeq 6000 shipments worldwide and NextSeq 550 placements in China, plus a drop in MiSeq shipments as customers move over to NextSeq 1K/2K; demand for NextSeq 1K/2K stayed strong among customers new to Illumina, with shipments up 8% year-over-year. Sequencing service and other revenue for Core Illumina reached $134 million, rising 7% year-over-year, mainly because of higher instrument service contract revenue on a larger installed base, partly offset by smaller contributions from codevelopment partnerships. Now to regional results for Core Illumina. Budget constraints and limited funding kept weighing on all geographies, shaping the way customers approach project planning and buying choices. Beyond that, each region also saw the impact of high-throughput clients transitioning to NovaSeq X, and what we noticed was that those customers reduced their purchases of NovaSeq 6K consumables ahead of their NovaSeq X activity reaching full scale. This effect, as Chuck noted, was expected, but it got amplified because NovaSeq X deliveries came in at a higher volume than anticipated and because those instruments were brought online more slowly than expected during Q2. Continued worldwide appetite for NovaSeq X instruments, together with supply that came in stronger than we had anticipated in Q2, helped counterbalance these dynamics. The clinical side kept up its robust trajectory in the Americas, Europe, and AMEA as well, as consumables shipped to clinical clients in those areas rose a bit below 20% compared with the prior year. In Europe, additional tailwinds came from Germany's NIPT reimbursement ruling made last year along with the Dutch national NIPT initiative. Revenue in the Americas came to $623 million, a 2% drop versus a year earlier, while Europe posted $303 million, up 11% year-over-year, which becomes 14% when measured on a constant currency basis. AMEA brought in $118 million, a 10% year-over-year decrease, or 6% on a constant currency basis, a figure that reflects a 14 percentage point hit from sanctions that restrict our capacity to operate in Russia. Keep in mind that these regions were likewise still dealing with the year-over-year deceleration in COVID surveillance. Revenue in Greater China came to $115 million, down 3% from a year earlier, which works out to a 1% gain when measured in constant currency. Along with ongoing macroeconomic and geopolitical pressures weighing on the region, the local competitive environment hurt revenue as well, especially in mid-throughput. Now turning to the remaining parts of the Core Illumina P&L. Non-GAAP gross margin for Core Illumina landed at 67.0%, a drop of 280 basis points versus the prior year. The main reasons were thinner instrument margins tied to the NovaSeq X launch — something we typically see during a launch year — plus reduced fixed cost leverage stemming from lower manufacturing volumes, and increased costs for field services and installation. On the Core Illumina side, non-GAAP opex came to $531 million, which is $12 million higher than the same period last year, largely driven by having our 2022 headcount growth in place for the entire year. We actually landed below our plan on non-GAAP opex, thanks to expense cuts happening sooner than anticipated and weaker performance-based comp. When you put all those pieces together, Core Illumina's non-GAAP operating margin for Q2 2023 was 21.2%, compared with 24.9% in Q2 2022. Turning now to how GRAIL performed financially: GRAIL brought in $22 million of revenue this quarter, which works out to 83% growth year-over-year, driven mostly by quicker adoption of Galleri. GRAIL's non-GAAP operating expenses came to $174 million, up $18 million from a year earlier, largely because of ongoing investments aimed at scaling up GRAIL's commercial organization. Turning next to consolidated cash flow and balance sheet items. Operations generated cash flow of $105 million. Capital expenditures for the second quarter of 2023 reached $47 million, while free cash flow stood at $58 million; no common stock was repurchased during the quarter. We closed out the quarter with roughly $1.6 billion in cash, cash equivalents and short-term investments. As you know, we hold $750 million in convertible debt set to mature this month. Additionally, the European Commission imposed a penalty of €432 million on Illumina on July 12, 2023, related to completing the GRAIL purchase before the Commission's assessment had finished. We intend to provide a guarantee and delay payment of that fine until the appeal concerning the EU General Court's decision — which determined that the European Commission has authority to examine the GRAIL deal — reaches a conclusion. Let's now turn to the 2023 guidance.
Joydeep Goswami
executiveOur updated outlook for consolidated revenue in full year 2023 is growth of about 1%, with Core Illumina revenue roughly level versus 2022. Keep in mind that these ranges factor in roughly 200 basis points of expected reduction from COVID surveillance, about 100 basis points of impact on our business from Russia sanctions, plus a negative year-over-year effect from foreign exchange rates. For GRAIL, revenue for 2023 is still projected at $90 million to $110 million. Looking ahead to fiscal 2023, our updated outlook calls for Core Illumina sequencing instrument revenue to rise roughly 3% compared with the prior year. That figure reflects an improved forecast for NovaSeq X units shipped, though it is partially counterbalanced by limits on capital and cash flow that continue to shape customer purchasing behavior, China included. That market additionally felt a stronger hit from domestic rivals, primarily in the mid-throughput segment. We're also forecasting that Core Illumina sequencing consumables revenue will decline roughly 3% compared to last year. There are four main reasons for this. First, funding challenges are lasting longer and customers are being more careful with purchases, which pushes projects back. Second, NovaSeq 6000 sequencing is dropping more sharply as we prepare to move to NovaSeq X, and part of that is because we now expect to ship more NovaSeq X units. Third, the consumables ramp on NovaSeq X is taking longer than anticipated. And fourth, China's recovery in the second half is coming along more slowly than we thought. For 2023, our updated expectations are annual pull-through of about $800,000 to $900,000 per instrument for NovaSeq 6000, $80,000 to $130,000 for NextSeq 550, and $30,000 to $40,000 for MiSeq. For NextSeq 1K/2K, pull-through should still fall inside the historical guidance range of $120,000 to $170,000, while MiniSeq pull-through remains within its historical range of $20,000 to $25,000 per instrument. On the Core Illumina sequencing side, we're looking at something close to flat compared with last year. Within that number is about $30 million in intercompany sales into GRAIL, and those get eliminated when we consolidate. For consolidated non-GAAP operating margin, our expectation now sits at roughly 5%, while Core Illumina's non-GAAP operating margin comes in around 20%. The updated margin outlook mirrors both the softer revenue we're anticipating this year and weaker gross margins tied to reduced manufacturing volumes and the fixed cost leverage that comes with them. Those pressures are partly countered by speeding up the expense reduction programs Chuck brought up earlier — more than $100 million on an annual run rate basis — which touch headcount, real estate, and other areas. For 2023, our non-GAAP tax rate is now projected at roughly 41%. That figure still reflects an estimated $75 million hit to tax expense tied to R&D capitalization rules. The dollar amount of that non-GAAP tax expense impact from R&D capitalization requirements is unchanged, but because our earnings came in lower, the effect on our effective tax rate for 2023 has grown. On a non-GAAP basis, we now anticipate diluted earnings per share for 2023 of between $0.75 and $0.90. That range still accounts for dilution stemming from GRAIL's non-GAAP operating loss, which is approximately $670 million. Before opening the line for questions, I want to walk through our guidance for the third quarter of 2023. For the third quarter of 2023, our consolidated revenue is anticipated to increase roughly 2% compared to the same period last year, reaching about $1.14 billion. That represents a sequential drop of around 320 basis points from the second quarter of 2023, largely because NovaSeq 6000 consumables declined sequentially as customers keep moving over to NovaSeq X; when it comes to Q3, we're looking at non-GAAP diluted EPS in the range of approximately $0.10 to $0.15, which would mean a consolidated non-GAAP operating margin of roughly 4% alongside a Core Illumina non-GAAP operating margin of about 19%. At this point I'd like to hand things over to the operator to begin the Q&A session. Thank you.
Puneet Souda
analystRegarding the difficulties you're encountering with NovaSeq in the marketplace, could you speak to that a bit? How quickly are you able to resolve these problems? What's driving this recovery? And what are the implications for installs during Q3 and Q4, and potentially even 2024? What I'm asking is whether the market essentially pauses until these issues get worked out before committing to additional instruments. Then, concerning demand elasticity, obviously there's a considerably steeper drop this year — sequencing consumables have fallen compared with what we saw at the last product launch, that of NovaSeq 6000. You listed several factors, but I'm just trying to gauge what portion of this stems from the field challenges you're dealing with. And look, NovaSeq is clearly still selling in spite of those challenges, so perhaps you could also give us an update on the CEO search?
Charles Dadswell
executiveI've been listening to you folks for quite a while now, and it's great to be able to take part in the discussion. So when it comes to NovaSeq X, among the bright spots of launching an instrument of this scale is that we've placed a greater number of instruments than we had anticipated; it also involves some of the largest software placements we've ever had; and it's revolutionary from the ground up. What happened is we underestimated how much time it would ultimately require to get these instruments online; but our technical teams are collaborating with our customers to get them up to speed as fast as we're able.
Joydeep Goswami
executivePuneet, let me step in here. There are a few points to make. To start with, as you're aware, whenever you roll out something of this scale, once you're in the field and beginning installation, certain defects surface that need fixing. What we observed during Q2 was completely typical. In fact, we've already got remedies in place for the problems identified, and those remedies are currently being rolled out to our customers. That has caused a slight slippage from what we initially anticipated regarding when these machines would reach full performance; however, nothing has shifted in terms of what we or our customers expect from NovaSeq X; and I'd also strongly encourage you to keep in mind that not every customer encounters this. Certain customers are entirely <<inaudible>>, whereas for others who have run into these problems, we've got everyone fully committed to resolving them on site. On the second point, you brought up elasticity regarding growth in volume and growth in sequencing volume. Well, no basic shift in elasticity is apparent to us. What you're observing ties more to the move toward the X. The result has been that, given the greater quantity of X units placed in that region because we accelerated delivery of some X supply, the drop in 6k consumables came faster and proved bigger than anticipated. Once more, this reflects the other side of customers being genuinely enthusiastic about the X and our capacity to ship additional X units. That's the situation. The decline is short-term. We anticipate that once we've completely ramped the X units, that volume will return through X consumables. What you're witnessing at present, though, is the timing gap separating those two events; and you raised something about — I believe it was — if these X-related difficulties are persisting or will bring about a market stall. In fact, no market stall has occurred. Demand for the X along with our late stage pipeline keeps climbing. As Chuck noted during his prepared remarks, we've watched the X genuinely unlock experiments and solutions that previously weren't achievable. So ongoing enthusiasm for the X persists, as does enthusiasm for accomplishing things that couldn't be done before. And, Chuck, I'll hand things back to you regarding the CEO search.
Charles Dadswell
executiveWhen it comes to the hunt for a CEO, the board is actively looking for the person who will take on that role. Candidates are being considered from inside the company as well as from outside. The caliber of the people they've been meeting with has left them genuinely encouraged; naturally, though, the specifics of how the board handles this matter are kept confidential. As soon as we're in a position to do so, we'll share an update with you.
Dan Brennan
analystI suppose there are a few things bundled together here. Regarding that flow cell at $25 billion, does it remain on schedule? Given a few of the problems you mentioned, when is it going to be delivered? The second item is China. China did expand during the quarter, yet I'm aware you pointed to certain strains there. So what is currently assumed for China across the latter half of the year? The third item would be the difficulties with reference customers everywhere, which clearly the wider tool categories found genuinely tough in the second quarter, but even so, the academic and government end market has in fact been rather strong outside of China; therefore I'd like to know whether you could talk a bit about where these difficulties are appearing. And the last item would simply concern the NovaSeq consumable pull-through card, and you're saying customers are moving more quickly onto the X. I suppose, how do we become confident that you aren't experiencing either some competitive effect or some reduction in utilization? What do you think was different on this occasion, in terms of your forecasting versus <<inaudible>> management forecasted during the previous cycle?
Charles Dadswell
executiveI believe, firstly, we keep giving priority to our investments. They are proprietary, and we remain focused on differentiating our products. We likely possess the largest and finest proprietary pipeline within the industry. And we keep relying on it. The 25b flow cell is still on schedule to launch in the second half of 2023. We keep advancing the Illumina CLR enrichment assay. That is especially persuasive when it's used alongside the 25B flow cell. We keep progressing the X-LEAP SBS chemistry for NovaSeq 1k/2k; and we will have upcoming offerings for emerging markets covering areas such as proteomics, multiomics, and spatial
Joydeep Goswami
executiveOkay, I'll hop in on the China piece. So yes, similar to what other businesses have reported, the recovery we saw during the back half of the year came in below what we'd anticipated. Keep in mind, our expectation had been that China would be somewhat weak through the first six months while working past the COVID-related difficulties. After that, we thought the rebound would pick up pace during the latter six months; at present, that pickup isn't materializing, partly because of the broader economic headwinds you're all aware of in China, and partly because we're facing greater competitive pressure there in both the mid throughput and low throughput categories. The other half of your question dealt with everything outside China, correct? Over there, I wouldn't characterize things as being as severe as they were a year ago. What we're observing is a degree of caution tied to economic uncertainty, which affects how quickly customers return to buying or come back online. As a result, purchasing timelines have stretched out somewhat, affecting our instrument business for mid throughput and low throughput as well as certain consumables. Demand itself, as I mentioned, is still solid — it's simply that new projects and new instrument orders are arriving more slowly than we'd projected. Our win rate — and we monitor this quite carefully — across mid throughput and, naturally, high throughput, is still elevated; actually, it edged up a bit from Q1 to Q2. So once again, what I'd point to is more a stretching of timelines and buying cycles rather than any competitive dynamics in those areas. When it comes to the X, competition isn't a factor whatsoever. As I said, we're witnessing sustained and robust interest from our current customers, naturally, plus from newer buyers or those stepping up from mid throughput; our capacity to actually get these instruments delivered keeps that interest alive. As Chuck noted, regarding what these instruments make possible, a whole new array of larger-scale experiments lies ahead. Once again, this serves as a leading indicator for us. Clearly, customers haven't fully ramped on the X yet; much of it comes down to shifting over to the X and harnessing the numerous capabilities it delivers, well past simply the pricing dimension. That includes the onboard DRAGEN, quicker performance, a streamlined workflow, and of course the ambient ship reagents; so many elements factor in, beyond just the idea of, oh, this will give us a better price per Gb.
Dan Arias
analystJoydeep, clearly there are a lot of moving pieces on both the top line and the OpEx line. It seems like your cost reduction and expense management efforts are part of a multiyear effort. Given how this year is shaping up, how are you thinking about op margins for the core business next year relative to the 25% target you mentioned last quarter?
Joydeep Goswami
executiveA few things. First, you're right, we began as we said we would on our Q1 earnings call; we began a broad examination of our cost structure. And at the end of Q1, we actually moved ahead with starting a cost reset that we've carried out and have actually removed on a run rate basis more than $100 million annually in cost. In the second half of the year, given some of the uncertainties in the broader economic space, we continue to watch managing expenses very closely and to be very careful about directing expenses to the highest return areas, including the innovation areas that Chuck discussed. Given the challenges we're facing this year, obviously, we acknowledge that reaching those margins next year is going to seem like a stretch, but we remain very committed to planning for and delivering on those margins. And that's how we're proceeding.
Vijay Kumar
analystMy question had two parts, and it's mainly about the guidance. In Q3, I believe you mentioned 3%. The comparisons you'll face in Q4 appear fairly undemanding. And from what I've observed over time, your revenue has climbed sequentially every time going from Q2 onward. Well, if you look at how your Q2 trends played out sequentially, instruments rose, consumables rose, pull-through per box rose, and China rose. So is there any extra headwind we ought to factor in for the second half? What's the reason your second half wouldn't track the usual historical pattern? And here's something related, I think. You brought up 800,000 to 900,000 pull-through on the Nova 6k. I think some worry has surfaced. Pull-through on the NovaSeq X could potentially be weaker given the lower sample price point. Perhaps you could take us through what assumptions you're making regarding pull-through for the Nova X? Might we possibly witness a rebound, since my assumption is that customer inventory levels right now are quite low and they'll need to restock?
Joydeep Goswami
executiveThat question was long and had multiple parts. So let me attempt to unpack some of it; first, regarding the full year guidance, since it has been lowered, the pieces involved roughly land in three groups. Roughly 25% of the guidance cut truly stems from China. And as I said before, with China, that breaks into two things. We're observing a recovery in the broader economy that's slower than anticipated, including certain liquidity difficulties mostly for our clinical customers; and we're observing stronger competitive intensity impacting the mid throughput and low throughput segments. That accounts for 25%. The remaining 75% splits in roughly equal halves between two buckets. So one bucket concerns the shift toward the X and the gap we're observing when it comes to high throughput consumables, correct? And this stems from 6k consumables declining rather quickly as customers make plans to move to the X, and it gets somewhat worsened by the greater quantity of Xs we're delivering; and the other bucket is a ramp up on full utilization of the X that's slightly slower than anticipated. The remaining 50% of that 75% arises from a degree of customer conservatism we're observing, meaning longer sales cycles and a recovery that's slower than anticipated across the board outside China. So now Q2 compared with Q1 and then Q3 compared with Q2, we did witness a ramp up from Q1 to Q2 along many dimensions. Naturally, we shipped additional Xs. So we saw an increase on the instrument side. We saw a solid ramp up in our 6k consumables, mostly fueled by the clinical segment. And you're correct, we did in fact see an increase from Q1 to Q2 in China. But that was anticipated since China was truly depressed for us and other companies in Q1. Turning to Q3 now — the sequential decline you're noticing comes down to a couple of major factors, correct? First, that 6k consumable pullback I mentioned earlier will reach something like a local peak, since we anticipate a bigger shift over to the X, meaning we're sending out more X units. That drag on 6k consumables is only going to grow. Meanwhile, our X consumables haven't fully ramped yet, correct? That should happen in Q4, and I'll circle back to it. On top of that, we anticipate China will be somewhat lower than Q2, once again driven by the recovery moving along, unfortunately, at a slower pace than we'd anticipated. Then there's the final point on this — we anticipate Q4 will be considerably higher, and Q4 marks the first period where you genuinely begin to see X consumables arrive. You're seeing the usual seasonal year-end pickup in certain company spending, so that's still showing up, and we've factored it into our guidance. The final item you brought up concerns pull through. Incidentally, we haven't provided pull through figures for X. Just like with every new instrument, we'll release that only after the instrument ramp has settled into a stable state. So given the enthusiasm for X, plus the types of cohort studies and experiments customers keep telling us they wish to run on X, we anticipate our original assumptions and pull through remain warranted; regarding NovaSeq 6000, which is likely the one you meant, we've lowered our pull through figures for this year; however, that stems largely from the move to X and the bigger-than-anticipated effect of that shift, which I already covered.
Tejas Savant
analystFirst, Chuck, regarding the shifts in leadership here. Joydeep, you're welcome to jump in too. Dan inquired about margins and your pledge to 25%, and you described that as somewhat of a stretch, though clearly something you remain dedicated to. Would that same kind of framing also hold for the mid-teens girls you mentioned on analyst day for Core Illumina? Chuck, on the leadership transitions, past the CEO position, obviously the searches for CTO and CMO are also in progress. Is there anything you can offer about the reasoning driving that? Regarding the base business itself, with NovaSeq, placements for the X evidently arrived, I believe it was 28 to 30 units beyond where we had been, yet sequencing instrument revenue only surpassed our expectations by roughly 5% to 6%. So the real question is whether you're encountering more aggressive discounting. Is that something Illumina is driving forward because of the macroenvironment? You mentioned BGI beginning to be competitive in China, but any insight on the pricing dynamics for instruments would also be useful.
Charles Dadswell
executiveRegarding the executive team and the process here, I think the first thing we should do is thank both Alex and Phil for everything they've contributed to Illumina. With Alex, what we know is that he's headed to a new position. He'll become the CEO at another company; and I think we should feel genuinely proud to witness the kind of leadership we develop at Illumina. So Alex began at Illumina, moved to GRAIL, returned to Illumina, and now he's going to end up as a CEO. And we're all eager to see where that will be. We have a very deep bench within our R&D program. And it's truly encouraging to see employee number four, Steve Barnard, who was the first scientist the company ever brought on, stepping into that role. He understands the technology, he understands the team, and he'll be able to continue seamlessly from where Alex stopped. For the Chief Medical Officer, we're going to take some time and examine that organization. We're going to assess our position on the clinical side and on the medical side. Our dedication to our clinical customers, our clinical markets, and our clinical programs remains, and we'll launch that search once we've had time to look at exactly where that organization fits and what we require.
Joydeep Goswami
executiveTo follow up on your remaining questions, first, regarding margins and the mid-teens long-term growth that's implied — well, our outlook for that mid-teens long-term growth hasn't shifted at all, and as you're aware, it rests on a couple of pillars. The first is a big market that keeps expanding, where NGS penetration remains low, plus our capacity, through the innovations we bring, to serve that market's core NGS requirements and let Illumina capture a share that keeps getting bigger. That shows up as sequencing volume growth across the three dimensions I referenced before: first, a steadily rising count of samples, with more cohorts plus areas such as spatial and single cell really fueling more of that; a growing count of analyses for each sample — which again is really powered by NGS taking on more of the multiomics side of what our customers want answered; and finally, simply greater sequencing intensity, correct? So as you head toward bigger panels, as you do additional work in liquid biopsy, or areas like MRD. So every one of those stays in place. What I think we're truly watching for over roughly the coming year, as X sort of comes online and opens up a lot of these moves into the things we discussed, is how fast does that ramp occur? Yet over the long term, nothing we had guided to has really shifted in our thinking, and we're eager to see how X sort of carries us along that path. You'd raised two more questions. One concerned — the X and the fact that revenue growth on the instrument side isn't all that high. As I said, right, we're quite happy that we managed to deliver on the X and scale our supply far quicker than we'd anticipated. I think that's beneficial over the long run. What counterbalanced that bigger count of Xs was a pair of things I brought up earlier. First, we did observe on the China side that we had a smaller than anticipated number of mid-throughput and low throughput instruments. And broadly, overall, because purchasing cycles have lengthened somewhat, we did see weaker than anticipated mid-throughput and low throughput instrument sales around the globe. Now, unlike China, where competitive intensity played a role, across the rest of the world we actually didn't see our win rate decline. We actually watched it rise a bit in Q2. Also, when it comes to pricing, we monitor this quite closely, right? So in China, yes, we're being extremely surgical about when to deploy price and depending on the kind of customer. But we did observe a price decline overall in China. Across the rest of the world, our price actually stays on track with where we expected it to be. And we're moving forward with our plan of leveraging pricing as a tool to drive quicker uptake of the technologies we offer.
Sung Ji Nam
analystI just want a clarification regarding that more careful buying activity — does it mainly apply to your academic clients? Or does it show up in the clinical side too? And then, apologies if this was already covered, but what share of the slowdown in consumables orders would you attribute to the introduction of the higher density product, the 25B, and people holding off for improved economics when it comes to sequencing?
Joydeep Goswami
executiveThat more cautious purchasing, once again, generally speaking, outside of China, shows up in both the academic and clinical segments, correct? The drivers differ somewhat. Many of our clinical customers, I'd say, aren't profitable businesses. So they're handling their cash the way you'd anticipate; and even though sequencing remains central to what they do, their buying intensity has dropped off less rapidly than we had anticipated. As for your second question about how much of a hold-up exists for 25B, I don't believe there is any hold-up with 25B. What I was attempting to explain is that the full-year guidance reset — roughly 25% of it stemmed from the China effect, while the remaining 75% — and around 50% of that 75% — essentially boiled down to the effect on high throughput consumables stemming from the transition on X. That covers, as I mentioned, more of a transition on the 6k happening faster, plus a slight hold-up, because of certain problems I referenced in Q2 for which we're already putting solutions into the field. A small hold-up is working its way through during 2023.
Rachel Vatnsdal
analystStarting with the outlook, you reduced the midpoint of this year's revenue growth guidance by 750 basis points. You went through several of the shifting factors, including a more cautious CapEx climate in China plus certain lower consumables as customers move over to the new platform; so could you provide a finer-grained split of that 750 basis point reduction? How does it actually divide among those 3 areas? As a follow-up, I'd like to ask about a few of the earlier remarks concerning China, mostly tied to some of those stimulus packages. We've heard another tranche of stimulus might come in 4Q. So what are you picking up about stimulus packages? I realize you weren't seeing much benefit in 1Q, but did anything show up in 2Q? And after that, how is stimulus factored into guidance for the back half of the year?
Joydeep Goswami
executiveI gave the breakdowns before. So very briefly, Rachel, I'd say roughly 25% of that guidance reset truly stems from the China impact. Out of the remaining 75%, about 50% of that 75% actually came from the effect on high throughput consumables tied to the transition to the X. Then the other 50% is a bit of the cash conservatism we're observing among customers outside of China. Right? So that's approximately how we view the math; in China, to begin with, no stimulus is included in our expectations for the second half of the year. It never was in our guidance either. From what we could tell, stimulus during the first half of the year helped the industrial segments more, and we don't participate in those. And there is no — we didn't observe any stimulus in the second half — sorry, the second quarter either, right? So it's consistent. We haven't included it, and we hadn't at the outset either.
John Sourbeer
analystPerhaps only a few points of clarification. We're grateful you reaffirmed the long-term guidance in the mid-teens. Even so, it does seem as if certain headwinds in China might be structural, given some of the heightened competition there. I suppose my question is whether the long-term outlook for that market has shifted in any way. And a quick follow-up on the Complete Long Reads — is there anything you can share? What sort of demand are you observing for that launch?
Joydeep Goswami
executiveI'll address them one at a time. Regarding China and its long-term outlook, China continues to be a significant market for us. We remain dedicated to serving our customers there. Our brand in China is in fact quite strong, and once again, we stay committed to serving that market. That said, in light of certain shifts we are witnessing, we will keep refining our approach regarding how we go to market in that country, the types of partners we select so as to reach the pertinent segments — the fastest-growing portions of the market — better and more efficiently. So none of that has changed. Yet we keep watching how China will develop from where it stands now, as do most others in our field. As for Illumina Complete Long Reads, interest in it has been extremely high, correct? A great many customers have adopted the existing WGS product and are actively using it. Honestly, we had always expected that the genuine leap into this technology would originate from the enrichment product, which we remain on schedule to deliver, though that is also tied — because of the economics at play — really tied to the introduction of the 25B flow cell, correct? So that is still arriving toward the close of this year and should truly accelerate as we move into 2024.
Salli Schwartz
executiveWe appreciate your being with us once more. Just a note that you'll be able to access a recording of today's session over in the Investors area on our site; that wraps up this call, and we hope to connect with you at the conferences and other events we have coming up.
Operator
operatorThank you. That brings today's conference to a close. We appreciate you taking part. Have a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.